HSBC Holdings
CYTK icon

HSBC Holdings’s Cytokinetics CYTK Stock Holding History

HSBC Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Sell
151,125
-70,874
-32% -$5.09M 0.01% 896
2026
Q1 		$14.6M Buy
221,999
+218,303
+5,906% +$13.9M 0.01% 827
2025
Q4 		$235K Sell
3,696
-310
-8% -$19.3K ﹤0.01% 2625
2025
Q3 		$220K Buy
+4,006
New +$165K ﹤0.01% 2449
2023
Q4 		– Sell
-13,804
Closed -$414K – 2756
2023
Q3 		$414K Buy
+13,804
New +$460K ﹤0.01% 2062
2023
Q1 		– Sell
-17,734
Closed -$802K – 2755
2022
Q4 		$802K Buy
+17,734
New +$763K ﹤0.01% 2075
2022
Q2 		– Sell
-19,472
Closed -$727K – 3281
2022
Q1 		$727K Buy
19,472
+13,639
+234% +$485K ﹤0.01% 2158
2021
Q4 		$266K Buy
+5,833
New +$225K ﹤0.01% 2863

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's CYTK Position: Q2 2026 in Review

HSBC Holdings reduced its Cytokinetics (CYTK) stake by 32% in Q2 2026, selling an estimated $5.09M and leaving 151,125 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #896.

HSBC Holdings first reported a position in CYTK in Q4 2021 and has held it in 8 quarters since. The position peaked at $14.6M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • HSBC Holdings held 151,125 shares of Cytokinetics worth $12.9M as of Q2 2026.
  • HSBC Holdings sold 70,874 Cytokinetics shares in Q2 2026, an estimated $5.09M.
  • Cytokinetics made up 0.01% of HSBC Holdings's portfolio in Q2 2026, its #896 holding.
  • HSBC Holdings first reported a position in Cytokinetics in Q4 2021 and has held it in 8 quarters since.
  • HSBC Holdings's Cytokinetics position peaked at $14.6M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.